Form 4: Xenon CEO Sells Shares Under Pre-Arranged 10b5-1 Plan
Insider Transaction Report
Xenon Pharmaceuticals Inc.'s President and CEO, Ian Mortimer, sold a total of 25,205 common shares in December 2025 under a pre-arranged 10b5-1 trading plan.
Summary
- Ian Mortimer, President & CEO and Director of Xenon Pharmaceuticals Inc. (XENE), reported sales of common shares.
- The transactions occurred on December 5, 2025, and December 8, 2025.
- A total of 25,205 common shares were sold across three separate transactions.
- All sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Mortimer on September 27, 2024.
- On December 5, 2025, 14,375 shares were sold at a weighted-average price of $45.03, with individual prices ranging from $45.00 to $45.135.
- On December 8, 2025, 8,820 shares were sold at a weighted-average price of $45.59, with individual prices ranging from $45.02 to $46.013.
- Also on December 8, 2025, an additional 2,010 shares were sold at a weighted-average price of $46.32, with individual prices ranging from $46.02 to $46.49.
- Following these reported transactions, Mr. Mortimer directly beneficially owns 6,000 common shares and indirectly owns 14,300 common shares through his spouse.
Sentiment
Score: 5
Explanation: The sentiment is neutral. Sales made under a pre-arranged Rule 10b5-1 trading plan are typically for personal financial planning or diversification and do not inherently signal a change in management's outlook on the company's prospects.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
Insider transactions, particularly those executed under Rule 10b5-1 plans, are a routine part of executive compensation and personal financial management in the pharmaceutical industry and across public companies. These pre-arranged plans allow insiders to sell shares without being accused of trading on material non-public information.
Stakeholder Impact
- Shareholders: The impact on shareholders is likely minimal. Sales under a 10b5-1 plan are pre-scheduled and generally do not carry the same negative signaling as unplanned insider sales, as they are not indicative of a sudden loss of confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 09/27/2024 | Rule 10b5-1 trading plan adopted by Ian Mortimer. |
| 12/05/2025 | Sale of 14,375 common shares by Ian Mortimer. |
| 12/08/2025 | Sale of 8,820 common shares by Ian Mortimer. |
| 12/08/2025 | Sale of 2,010 common shares by Ian Mortimer. |
| 12/09/2025 | Date of filing of the Form 4. |
Keywords
Xenon Pharmaceuticals, XENE, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, CEO, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.